ArticleVirology journal2022
An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs.
Article in Virology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Advances in Adjuvanted Rabies Vaccines.Vaccines · 2026Review
- Working towards a single-dose vaccine for rabies post-exposure prophylaxis.Future virology · 2026Article
- Messenger RNA Nanomedicine: Innovations and Future Directions.Current protein & peptide science · 2026Review
- A Rabies Virus Nucleocapsid-like Nanostructure Vaccine Based on Dual-Cationic Lipid Nanoparticles.Vaccines · 2025Article
- Harnessing the Potential of mRNA Vaccines Against Infectious Diseases.Microbial biotechnology · 2025Review
- Novel rabies vaccine candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein.PLoS neglected tropical diseases · 2025Article
- Development of an mRNA vaccine encoding IHNV glycoprotein protects rainbow trout (Oncorhynchus mykiss) from infection.NPJ vaccines · 2025Article
- Immunogenicity, Efficacy and Twelve-Month Storage Stability Studies of a Lyophilized Rabies mRNA Vaccine.Vaccines · 2025Article
- Review
- Exploring one health-based strategies for rabies elimination: Overview and future prospects.PLoS neglected tropical diseases · 2025Review
- Rabies virus large protein-derived T-cell immunogen facilitates rapid viral clearance and enhances protection against lethal challenge in mice.Communications medicine · 2025Article
- A VSV-based oral rabies vaccine was sentineled by Peyer's patches and induced a timely and durable immune response.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Optimizing rabies mRNA vaccine efficacy via RABV-G structural domain screening and heterologous prime-boost immunization.NPJ vaccines · 2025Article
- Infection and Prevention of Rabies Viruses.Microorganisms · 2025Review
- Review
- Avian influenza mRNA vaccine encoding hemagglutinin provides complete protection against divergent H5N1 viruses in specific-pathogen-free chickens.Journal of nanobiotechnology · 2025Article
- Development of mRNA rabies vaccines.Human vaccines & immunotherapeutics · 2024Review
- A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice.Emerging microbes & infections · 2024Article
- IL-7 promotes mRNA vaccine-induced long-term immunity.Journal of nanobiotechnology · 2024Article
- Self-assembling nanoparticle engineered from the ferritinophagy complex as a rabies virus vaccine candidate.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabies is a lethal zoonotic disease that is mainly caused by the rabies virus (RABV). Although effective vaccines have long existed, current vaccines take both time and cost to produce. Messenger RNA (mRNA) technology is an emergent vaccine platform that supports rapid vaccine development on a large scale. Here, an optimized mRNA vaccine construct (LVRNA001) expressing rabies virus glycoprotein (RABV-G) was developed in vitro and then evaluated in vivo for its immunogenicity and protective capacity in mice and dogs. LVRNA001 induced neutralizing antibody production and a strong Th1 cellular immune response in mice. In both mice and dogs, LVRNA001 provided protection against challenge with 50-fold lethal dose 50 (LD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.